biostudies-literatureArnold SMNCI NIH HHS252-259https://www.ebi.ac.uk/biostudies/studies/S-EPMC5514161biostudies-literatureUnknown1(4)<h4>Purpose</h4>Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN).<h4>Experimental design</h4>Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m²) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity.<h4>Results</hAdvances in radiation oncologyUsing low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial.PMC5514161P30 CA177558Valentino JKudrimoti MGleason JFDressler EVSilver NLArnold SMRegine WFfalseUsing low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial.<h4>Purpose</h4>Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN).<h4>Experimental design</h4>Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m²) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity.<h4>Results</h2016-01-01T00:00:00Z2016 Oct-Dec2025-04-05T11:21:36.127Z2019-03-27T02:50:43ZS-EPMC55141612874089510.1016/j.adro.2016.06.003